ClinicalTrials.gg
CompletedNCT00944450Updated Aug 19, 2015Results posted

Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

A Phase 1 interventional study of Sitagliptin phosphate anhydrous formulation and Comparator: sitagliptin phosphate monohydrate form in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Merck & Co., Inc.

Enrollment
162nd of 170
12 · median 192
Started
2004
with 8 others
Phase 1
55 of 181
none open now
Registered
83rd of 181
by date

Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 162nd largest by enrollment of the 170 interventional ones that give a count, is one of 9 that started in 2004, is one of 55 in phase 1, and was the 83rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc as a file.
02

Study summary

This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is in good health
  • Female subjects must have a negative pregnancy test
  • Subject is within 30% of ideal body weight
  • Subject does not smoke
  • Subject agrees to follow the study guidelines

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of any illness that might confound the results of the study or make participation unsafe for the subject
  • Subject has a history of hypoglycemia
  • Subject has a history of any hepatic disease
  • Subject is taking any oral, parenteral, topical or implantable
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    1

    Sitagliptin anhydrous formulation

    Drug: Sitagliptin phosphate anhydrous formulation

  • Active comparator
    2

    Sitagliptin monohydrate FMI formulation

    Drug: Comparator: sitagliptin phosphate monohydrate form

Interventions

  • DrugSitagliptin phosphate anhydrous formulation

    Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.

  • DrugComparator: sitagliptin phosphate monohydrate form

    Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)

    Area Under the Plasma Concentration-Time Curve and peak concentration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)

    Time frame: Through 72 Hours Following the Administration of the Medication

  2. Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)

    Peak Plasma concentration (Cmax) for the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)

    Time frame: Through 72 Hours Following the Administration of the Medication

07

Results

Posted Apr 27, 2010

Participant flow

Period 1
Participant flow — Period 1
Milestone100 mg MK0431 Anhydrous Then 100 mg MK0431 Monohydrate100 mg MK0431 Monohydrate Then 100 mg MK0431 Anhydrous
Started66
Completed66
Not completed00
Period 2
Participant flow — Period 2
Milestone100 mg MK0431 Anhydrous Then 100 mg MK0431 Monohydrate100 mg MK0431 Monohydrate Then 100 mg MK0431 Anhydrous
Started66
Completed66
Not completed00

Outcome measures

PrimaryArea Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)

Area Under the Plasma Concentration-Time Curve and peak concentration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)

Time frame:
Through 72 Hours Following the Administration of the Medication
Reported as:
Geometric mean · μmol*hr/L
Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
μmol*hr/L100 mg MK0431 Anhydrous100 mg MK0431 Monohydrate
Area Under the Curve (AUC(0 to Infinity)) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)8.38 ± 0.778.78 ± 0.86
Statistical analysis
  • 100 mg MK0431 Anhydrous vs 100 mg MK0431 Monohydrate · Geometric mean ratio: 1.05 · 90% CI 1.02 to 1.07
PrimaryPeak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)

Peak Plasma concentration (Cmax) for the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)

Time frame:
Through 72 Hours Following the Administration of the Medication
Reported as:
Geometric mean · μmol/L
Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)
μmol/L100 mg MK0431 Anhydrous100 mg MK0431 Monohydrate
Peak Plasma Concentration (Cmax) Following Single Dose Administration of the Anhydrous and Monohydrate Forms of MK0431 (Sitagliptin)799 ± 164856 ± 180
Statistical analysis
  • 100 mg MK0431 Anhydrous vs 100 mg MK0431 Monohydrate · Geometric mean ratio: 1.07 · 90% CI 0.94 to 1.22

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
100 mg MK0431 Anhydrous Then 100 mg MK0431 Monohydrate—0/12 (0%)3/12 (25%)
100 mg MK0431 Monohydrate Then 100 mg MK0431 Anhydrous—0/12 (0%)5/12 (41.7%)
Most frequent other events
Most frequent other events
Event100 mg MK0431 Anhydrous Then 100 mg MK0431 Monohydrate100 mg MK0431 Monohydrate Then 100 mg MK0431 Anhydrous
HeadacheNervous system disorders3/122/12
NauseaGastrointestinal disorders1/121/12
VomitingGastrointestinal disorders0/121/12
AstheniaGeneral disorders0/121/12
Upper Respiratory Tract InfectionInfections and infestations0/121/12
Thermal BurnInjury, poisoning and procedural complications0/121/12
Musculoskeletal StiffnessMusculoskeletal and connective tissue disorders0/121/12
DizzinessNervous system disorders0/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean45.3 (41 to 54)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female6
Male6
Height
Height(Centimeters)All Participants
Mean170.5 (156.5 to 179.0)
Weight
Weight(Kilograms)All Participants
Mean75.3 (56.6 to 88.3)
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2004, a primary completion of Sep 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2009
First posted
Jul 23, 2009
Start
Aug 2004
Primary completionActual
Sep 2004
CompletionActual
Nov 2004
Results first posted
Apr 27, 2010
Last update
Aug 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00944450
Responsible party
Sponsor
First posted
Jul 23, 2009
Start date
Aug 2004
Primary completion
Sep 2004
Completion
Nov 2004
Results posted
Apr 27, 2010
Last update
Aug 19, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion